Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2025-08-22 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data such as total assets, net profit, revenue, and shareholder information for the half-year period. The text includes management discussion of risks, financial performance, and operational highlights typical of an interim or quarterly report. The document length is 4416 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. It explicitly states it is a summary of the half-year report and references the full report for more details. This fits the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the correct classification is IR with high confidence. H1 2025
2025-08-22 Chinese
益方生物2025年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by a company. It details the amount of funds raised, their deposit, usage, management, and compliance with regulatory rules related to raised funds. The document includes specific financial figures about the raised funds, their allocation, and usage during the half-year period ending June 30, 2025. It references regulatory rules from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes detailed tables on fund usage and management. This is a specialized report focused on the use of capital raised by the company, not a general financial report or earnings release. It is not an announcement of a report publication but the report itself, given the length and detailed financial data. The document fits the category of a Capital/Financing Update (CAP), as it provides a detailed update on the company's fundraising and the use of those funds during the half-year period.
2025-08-22 Chinese
益方生物关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by the company Yifang Bio-Technology (Shanghai) Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the board resolution, investment purpose, product types, risk control measures, and regulatory compliance related to the use of idle raised funds. The document references the approval by the China Securities Regulatory Commission for the IPO and the raised funds amount, but it does not contain financial statements or detailed financial performance data. It is a disclosure about capital management activities related to fundraising proceeds, not a full financial report or earnings release. The document length is about 2762 characters, which is relatively short and focused on a specific financing-related update. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-08-22 Chinese
益方生物董事会薪酬与考核委员会关于2022年限制性股票激励计划预留授予部分第二个归属期归属名单的核查意见
Share Issue/Capital Change Classification · 80% confidence The document is a decision/opinion by the Board’s Compensation and Assessment Committee concerning the vesting list for the second vesting period under the 2022 restricted share incentive plan. This relates to the reserved grant and issuance of restricted shares, i.e., a capital change/share issue under the company’s stock incentive plan. Therefore, it best fits the “Share Issue/Capital Change” category (Code: SHA).
2025-08-22 Chinese
君合律师事务所上海分所关于益方生物科技（上海）股份有限公司2022年限制性股票激励计划预留授予部分第二个归属期归属条件成就的法律意见书
Regulatory Filings Classification · 15% confidence The document is a formal legal opinion letter issued by a law firm regarding the vesting conditions and legal compliance of a restricted stock incentive plan. It does not itself provide financial results or management discussion, nor is it an AGM presentation, earnings release, or proxy statement. It is a professional legal attestation letter (“法律意见书”), which according to the Certification Rule and fallback guidelines should be classified as a general regulatory filing. Therefore, the correct category is Regulatory Filings (RNS).
2025-08-22 Chinese
益方生物关于2022年限制性股票激励计划预留授予部分第二个归属期符合归属条件的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the 2022 restricted stock incentive plan of Yifang Bio-Technology (Shanghai) Co., Ltd. It discusses the approval, implementation, and fulfillment of conditions for the second vesting period of reserved restricted stock grants. It includes specifics on stock quantities, vesting schedules, performance targets, board approvals, legal opinions, and registration of shares. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not related to earnings releases, capital updates, or legal proceedings. It is a regulatory announcement about stock-based compensation and the vesting of restricted shares, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance disclosure related to stock incentives and vesting conditions.
2025-08-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.